A Comprehensive Guide: When to Stop Procrit?
•
3 min read
In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when erythropoiesis-stimulating agents (ESAs) like Procrit were administered to target a hemoglobin level of greater than 11 g/dL. As a result, understanding **when to stop Procrit?** is crucial for balancing therapeutic benefits against potential risks, a decision guided by strict clinical protocols and patient-specific factors.
